DBCO-PEG8-VKG-CPT2

DBCO-PEG8-VKG-CPT2 is a drug-linker conjugate for ADC. DBCO-PEG8-VKG-CPT2 consists of a topoisomerase 1 inhibitor (7-MAD-MDCPT) (HY-132162) and a stable and cleavable linker (DBCO-PEG8-VKG) (HY-175426) . DBCO-PEG8-VKG-CPT2 can be used for synthesis of ADCs[1].

Product Specifications

UNSPSC

12352005

Target

Drug-Linker Conjugates for ADC; Topoisomerase

Related Pathways

Antibody-drug Conjugate/ADC Related; Cell Cycle/DNA Damage

Field of Research

Cancer

Smiles

O=C(NCCOCCOCCOCCOCCOCCOCCOCCOCCC(N[C@H](C(C)C)C(N[C@H](C(NCC(NCC(C1=CC2=C(C=C1N=C3C4=CC([C@]5(CC)O)=C6COC5=O)OCO2)=C3CN4C6=O)=O)=O)CCCCN)=O)=O)CCC(N7C8=C(C#CC9=C(C7)C=CC=C9)C=CC=C8)=O

Molecular Formula

C73H93N9O20

Molecular Weight

1416.57

References & Citations

[1]High PC, et al. Cetuximab increases LGR5 expression and augments LGR5-targeting antibody-drug conjugate efficacy in patient-derived colorectal cancer models. bioRxiv [Preprint]. 2025 Jun 24:2025.06.18.660406.